Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro

The FDA approval of two anti-HER2 monoclonal antibodies, trastuzumab and pertuzumab, and an antibody-drug conjugate, trastuzumab emtansine, has transformed clinical practice for HER2-positive cancers. However, not all patients respond to therapy, and the majority of responders eventually develop res...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hongqian, Wang, Yanping, Xiao, Zuoxiang, Li, Wei, Dimitrov, Dimiter S., Chen, Weizao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640707/
https://www.ncbi.nlm.nih.gov/pubmed/31544831
http://dx.doi.org/10.3390/antib8010025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640707/
https://www.ncbi.nlm.nih.gov/pubmed/31544831
http://dx.doi.org/10.3390/antib8010025

Ejemplares similares